Department of Pharmacology, Additional Professor & Head, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Puducherry, India.
Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2255-2261. doi: 10.31557/APJCP.2022.23.7.2255.
miRNAs are known to be aberrantly expressed in the serum, tissue, and Peripheral Blood Mononuclear Cells (PBMC) of cancer patients and could serve as potential noninvasive diagnostic markers for breast cancer. The aim of this study was to identify the differentially expressed miRNA using next-generation sequencing (NGS) from the paired PBMC samples from breast cancer patients and age-matched healthy individuals and explore their functional significance.
In this study, PBMCs were employed for the detection of miRNAs by NGS in locally advanced breast cancer (LABC) women of South Indian origin who were divided into three age groups, (a) 40yrs-50yrs (b) 50yrs-60yrs and (c) 60yrs-70yrs, compared with age-matched control groups.
Four miRNAs (hsa-miR-192-5p, hsa-miR-24-2-2p, hsa-miR-3609, and hsa-miR-664b-3p) were found to be differentially expressed among LABC patients compared with age matched healthy women of the South Indian population. While miR-24-2-5p, miR3609, and miR-664b-3p were down-regulated, miR-192-5p was up-regulated. Gene Ontology (GO) annotations implicated miRNA with signaling pathways in peripheral nerve synapses, glutamatergic synapse, and cell morphogenesis, all of which play a pivotal role in the manifestation of cancer.
Four miRNAs- 3 (While miR-24-2-5p, miR3609, and miR-664b-3p) downregulated and one upregulated (miR-192-5p) were identified as potential biomarkers for patients with locally advanced breast cancer. These markers could be validated in studies with a larger sample size.
已知 miRNA 在癌症患者的血清、组织和外周血单个核细胞(PBMC)中表达异常,可作为乳腺癌潜在的非侵入性诊断标志物。本研究旨在通过对来自印度南部局部晚期乳腺癌(LABC)女性和年龄匹配的健康个体的配对 PBMC 样本进行下一代测序(NGS),鉴定差异表达的 miRNA,并探讨其功能意义。
在这项研究中,我们使用 NGS 检测了来自印度南部的局部晚期乳腺癌(LABC)女性的 PBMC 中的 miRNA,这些女性被分为三个年龄组,(a)40-50 岁,(b)50-60 岁和(c)60-70 岁,与年龄匹配的对照组进行比较。
与年龄匹配的健康印度南部女性相比,LABC 患者中有 4 种 miRNA(hsa-miR-192-5p、hsa-miR-24-2-2p、hsa-miR-3609 和 hsa-miR-664b-3p)表达差异。miR-24-2-5p、miR3609 和 miR-664b-3p 下调,而 miR-192-5p 上调。GO 注释表明,miRNA 与外周神经突触、谷氨酸能突触和细胞形态发生的信号通路有关,这些通路在癌症的表现中都起着关键作用。
鉴定出 4 种 miRNA(3 种下调和 1 种上调),即 miR-24-2-5p、miR3609、miR-664b-3p 和 miR-192-5p,作为局部晚期乳腺癌患者的潜在生物标志物。这些标志物可以在更大样本量的研究中进行验证。